Hydroxyprogesterone caproate explained

Verifiedfields:verified
Verifiedrevid:477198932
Width:250
Width2:250
Tradename:Delalutin, Proluton, Makena, others
Routes Of Administration:Intramuscular injection, subcutaneous autoinjection
Class:Progestogen
Progestin; Progestogen ester; Antigonadotropin
Atc Prefix:G03
Atc Suffix:DA03
Atc Supplemental:
Legal Us:withdrawn
Bioavailability:Oral

Very low (~3% in rats)
Intramuscular: 100% (in rats)

Protein Bound:Extensive (to albumin, not to or (likely))
Metabolism:Reduction and hydroxylation (via CYP3A4, CYP3A5, CYP3A7) and conjugation (glucuronidation, sulfation, acetylation)
Elimination Half-Life:Non-pregnant: 7.8 days[1]
Singlet: 16–17 days
Twins: 10 days
Excretion:Feces

50%
Urine: 30%

Cas Number:630-56-8
Pubchem:169870
Drugbank:DB06789
Chemspiderid:148552
Unii:276F2O42F5
Kegg:D00949
Chebi:5812
Chembl:1200848
Synonyms:OHPC; Hydroxyprogesterone capronate; Hydroxyprogesterone hexanoate; 17α-Hydroxyprogesterone caproate; 17α-OHPC; 17-Hydroxyprogesterone caproate; 17-OHPC; 17-HPC; 17α-HPC; HPC; LPCN-1107; 17α-Hydroxypregn-4-ene-3,20-dione 17α-hexanoate
Iupac Name:[(8''R'',9''S'',10''R'',13''S'',14''S'',17''R'')-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1''H''-cyclopenta[''a'']phenanthren-17-yl] hexanoate
C:27
H:40
O:4
Smiles:O=C4\C=C2/[C@]([C@H]1CC[C@@]3([C@@](OC(=O)CCCCC)(C(=O)C)CC[C@H]3[C@@H]1CC2)C)(C)CC4
Stdinchi:1S/C27H40O4/c1-5-6-7-8-24(30)31-27(18(2)28)16-13-23-21-10-9-19-17-20(29)11-14-25(19,3)22(21)12-15-26(23,27)4/h17,21-23H,5-16H2,1-4H3/t21-,22+,23+,25+,26+,27+/m1/s1
Stdinchikey:DOMWKUIIPQCAJU-LJHIYBGHSA-N

Hydroxyprogesterone caproate, sold under the brand name Delalutin among others, is a medication used to reduce the risk of preterm birth in women pregnant with one baby who have a history of spontaneous preterm birth. In March 2023, the manufacturer, Covis Pharma, agreed to withdraw the drug from the US market.[2] [3] [4] The approval of this drug substance was withdrawn by the US Food and Drug Administration (FDA) in April 2023.[5] In May 2024, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended suspending the marketing authorizations of medications containing 17-hydroxyprogesterone caproate in the European Union.[6]

Hydroxyprogesterone caproate is a progestin medication which was used to prevent preterm birth in pregnant women with a history of the condition and to treat gynecological disorders.[7] [8] [9] [10] It has also been formulated in combination with estrogens for various indications (brand names Gravibinon and Primosiston) and as a form of long-lasting injectable birth control (brand name Chinese Injectable No. 1).[11] It is not used by mouth and is instead given by injection into muscle or fat.

Hydroxyprogesterone caproate is generally well tolerated and produces few side effects. Injection site reactions such as pain and swelling are the most common side effect of hydroxyprogesterone caproate. The medication may increase the risk of gestational diabetes when used in pregnant women. Hydroxyprogesterone caproate is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has some antimineralocorticoid activity and no other important hormonal activity.[12] The medication shows a number of differences from natural progesterone.

Hydroxyprogesterone caproate was discovered in 1953 and was introduced for medical use in 1954 or 1955. It was marketed in the United States under the brand name Delalutin and throughout Europe under the brand name Proluton. The medication was discontinued in the United States in 1999.[13] However, hydroxyprogesterone caproate was subsequently reintroduced in the United States under the brand name Makena for the treatment of preterm birth in 2011 untill the FDA banned 17α-OHPC in 2023.

Medical uses

Preterm birth

The use of hydroxyprogesterone caproate in pregnancy to prevent preterm birth in women with a history of preterm delivery between 20 weeks and 36 weeks and 6 days is supported by the Society of Maternal Fetal Medicine Clinic Guidelines put out in May 2012 as Level I and III evidence, Level A recommendation.[14] Level I evidence refers to a properly powered randomized controlled trial, and level III evidence is support from expert opinion, while a Level A recommendation confers that the recommendation is made based on good and consistent scientific evidence. Hydroxyprogesterone caproate 250 mg IM weekly preferably starting at 16–20 weeks until 36 weeks is recommended. In these women, if the transvaginal ultrasound cervical length shortens to <25 mm at < 24 weeks, cervical cerclage may be offered. In the 2013 study the guideline recommendation is based on,[15] there was also a significant decrease of neonatal morbidity including lower rates of necrotizing enterocolitis (0 in the treatment group vs 4 in the control), intraventricular hemorrhage (4 in the treatment group compared with 8 in the control for a relative risk of 0.25), and need for supplemental oxygen (14% in the treatment group vs 24% in the placebo for a relative risk of 0.42). Furthermore, this study contained 463 women, 310 of whom received injection. Of these women, 9 had infants with congenital malformations (2%), but there was no consistent pattern and none involved internal organs.

There is no evidence of fetal risk with use of hydroxyprogesterone caproate during pregnancy. A review concluded that information about the potential harms was lacking.[16] Three clinical studies in singleton pregnancies of 250 mg/week of intramuscular hydroxyprogesterone caproate have all shown a trend for an increase in pregnancy loss due to miscarriage compared to placebo.[17] [18] One of them, a large National Institutes of Health (NIH) study in 2003, looked at the effect of hydroxyprogesterone caproate injections in women at risk for repeat premature birth and found that the treated group experienced premature birth in 37% versus 55% in the controls. A follow-up study of the offspring showed no evidence that hydroxyprogesterone caproate affected the children in the first years of life.[19] Based on these NIH data, hydroxyprogesterone caproate was approved by the US Food and Drug Administration (FDA) in 2011, as a medication to reduce the risk of premature birth in selected women at risk.

The FDA expressed concern about miscarriage at the 2006 advisory committee meeting; the committee voted unanimously that further study was needed to evaluate the potential association of hydroxyprogesterone caproate with increased risk of second trimester miscarriage and stillbirth.[20] A toxicology study in rhesus monkeys resulted in the death of all rhesus fetuses exposed to 1 and 10 times the human dose equivalent of hydroxyprogesterone caproate.[21], hydroxyprogesterone caproate was a category D progestin according to the FDA (that is, there is evidence of fetal harm). There is speculation that the castor oil in the hydroxyprogesterone caproate formulation may not be beneficial for pregnancy.[22] [23] Of note, the above-mentioned NEJM study by Meirs et al. compares the effect of hydroxyprogesterone caproate (with the castor oil component) to castor oil injection as the placebo.

A study published in February 2016, found amongst other findings:[24]

The journal reviewer made the following notable commentary on the OPPTIMUM study: "That's it. This story is ended, and nobody need ever use vaginal progesterone again to prevent preterm birth."[25]

A Cochrane review on progestogen for preventing preterm birth concluded that there was little evidence that either vaginal or intramuscular progesterone helped to reduce the risk of preterm birth in women with a multiple pregnancy.[26]

Gynecological disorders

Hydroxyprogesterone caproate is used in the treatment of threatened miscarriage, gynecological disorders such as dysmenorrhea, premenstrual syndrome, fibrocystic breast disease, adenosis, and breast pain. In addition, hydroxyprogesterone caproate is used in the treatment of endometrial cancer and has been found to be significantly effective in extending life in both premenopausal and postmenopausal women with the disease.[27] The medication was used widely in the 1950s through the 1970s for such indications, but hydroxyprogesterone caproate more recently has received the most attention in the prevention of preterm birth.

Birth control

Hydroxyprogesterone caproate is available in combination with estradiol valerate as a once-monthly combined injectable contraceptive in a some countries.

Other uses

Hydroxyprogesterone caproate has been used as a component of menopausal hormone therapy in women.[28] [29]

Hydroxyprogesterone caproate has been used to treat benign prostatic hyperplasia in men, although evidence of effectiveness is marginal and uncertain.[30] It has also been used to treat prostate cancer, at a dosage of 1,500 mg twice per week.[31] [32] [33] The mechanism of action of hydroxyprogesterone caproate in these uses is suppression of testicular androgen production via suppression of luteinizing hormone secretion, which are the result of the progestogenic and antigonadotropic activity of hydroxyprogesterone caproate. However, symptoms of hypogonadism may develop when hydroxyprogesterone caproate is used for this indication, with two-thirds of men reportedly experiencing impotence.[34]

Hydroxyprogesterone caproate has been used as a component of feminizing hormone therapy for transgender women.[35] [36] [37] [38] [39] Due to micronization, bioidentical progestogens are more commonly used.

Available forms

See also: Estradiol valerate/hydroxyprogesterone caproate, Estradiol benzoate/hydroxyprogesterone caproate and Estradiol dipropionate/hydroxyprogesterone caproate.

Hydroxyprogesterone caproate is available alone in the form of ampoules and vials of 125 and 250 mg/mL oil solutions for intramuscular injection (brand names Proluton, Makena).[40] It is also available alone in the form of a 250 mg/mL autoinjector for use by subcutaneous injection (brand name Makena).

Hydroxyprogesterone caproate is or was available in combination with estradiol valerate in the form of ampoules and vials of 250 mg/mL OHPC and 5 mg/mL estradiol valerate oil solutions for intramuscular injection (brand names Gravibinon, Chinese Injectable No. 1).[41] [42] [43] [44] The medication is or was available in combination with estradiol benzoate in the form of ampoules of 125–250 mg OHPC and 10 mg estradiol benzoate in oil solution for intramuscular injection (brand name Primosiston) as well.[45] [46] [47] [48] In addition, hydroxyprogesterone caproate has been marketed in combination with estradiol dipropionate in the form of 50 mg/mL hydroxyprogesterone caproate and 1 mg/mL estradiol dipropionate (brand name EP Hormone Depot) in Japan.[49] [50]

Contraindications

Contraindications of hydroxyprogesterone caproate include previous or current thrombosis or thromboembolic disease, known or suspected breast cancer, past or present history of other hormone-sensitive cancer, undiagnosed abnormal vaginal bleeding unrelated to pregnancy, cholestatic jaundice of pregnancy, liver tumors or active liver disease, and uncontrolled hypertension. A few relative contraindications also exist for hydroxyprogesterone caproate.

Side effects

Hydroxyprogesterone caproate is generally well tolerated and produces relatively few side effects. Injection site reactions such as pain, soreness, swelling, itching, bruising, and lumps are the most common side effect of hydroxyprogesterone caproate. In contrast to large doses of progesterone however, which produce moderate-to-severe such reactions, hydroxyprogesterone caproate is relatively free from injection site reactions.[51] Side effects of hydroxyprogesterone caproate that occur in greater than or equal to 2% of users include injection site pain (34.8%), injection site swelling (17.1%), urticaria (12.3%), pruritus (7.7%), injection site pruritus (5.8%), nausea (5.8%), injection site nodules (4.5%), and diarrhea (2.3%). Numerically increased rates relative to controls of miscarriage (2.4% vs. 0%), stillbirth (2.0% vs. 1.3%), admission for preterm labor (16.0% vs. 13.8%), preeclampsia or gestational hypertension (8.8% vs. 4.6%), gestational diabetes (5.6% vs. 4.6%), and oligohydramnios (3.6% vs. 1.3%) have been observed with hydroxyprogesterone caproate in clinical trials in which it was given to pregnant women to prevent preterm birth.

Overdose

There have been no reports of overdose of hydroxyprogesterone caproate. In the event of overdose, treatment should be based on symptoms. Hydroxyprogesterone caproate has been studied in humans at high doses of 2,000 to 5,000 mg per week by intramuscular injection, without safety concerns.[52]

Interactions

Hydroxyprogesterone caproate is not likely to affect most cytochrome P450 enzymes at therapeutic concentrations. Drug interaction studies have not been performed with hydroxyprogesterone caproate.

Pharmacology

Pharmacodynamics

Hydroxyprogesterone caproate has progestogenic activity, some antimineralocorticoid activity, and no other important hormonal activity.

Progestogenic activity

Hydroxyprogesterone caproate, also known as 17α-hydroxyprogesterone caproate, is closer to progesterone in terms of structure and pharmacology than most other progestins, and is essentially a pure progestogen – that is, a selective agonist of the progesterone receptor (PR) with minimal or no other hormonal activity. However, hydroxyprogesterone caproate has improved pharmacokinetics compared to progesterone, namely a much longer duration with intramuscular injection in oil solution.[53]

Administered by intramuscular injection, the endometrial transformation dosage of hydroxyprogesterone caproate per cycle is 250 to 500 mg, and the weekly substitution dosage of hydroxyprogesterone caproate is 250 mg, while the effective dosage of hydroxyprogesterone caproate in the menstrual delay test (Greenblatt) is 25 mg per week.[54] [53] [55] An effective ovulation-inhibiting dosage of hydroxyprogesterone caproate is 500 mg once per month by intramuscular injection.[56] [57] However, the dose of hydroxyprogesterone caproate used in once-a-month combined injectable contraceptives is 250 mg, and this combination is effective for inhibition of ovulation similarly. For comparison, the dose of medroxyprogesterone acetate (MPA; 6α-methyl-17α-hydroxyprogesterone acetate), a close analogue of hydroxyprogesterone caproate, used by intramuscular injection in microcrystalline aqueous suspension in once-a-month combined injectable contraceptives, is 25 mg. It has also been said that given by intramuscular injection, 250 mg hydroxyprogesterone caproate in oil solution is equivalent in progestogenic potency to 50 mg medroxyprogesterone acetate in microcrystalline aqueous suspension.[58] Although the elimination half-life of intramuscular hydroxyprogesterone caproate in oil solution in non-pregnant women is about 8 days, the elimination half-life of intramuscular medroxyprogesterone acetate in microcrystalline aqueous suspension in women is around 50 days.[59] Hydroxyprogesterone caproate is also to some degree less potent than the more closely related ester hydroxyprogesterone acetate (OHPA; 17α-hydroxyprogesterone acetate).

17α-Hydroxyprogesterone (OHP) has weak progestogenic activity, but C17α esterification results in higher progestogenic activity. Of a variety of different esters, the caproate (hexanoate) ester was found to have the strongest progestogenic activity, and this served as the basis for the development of hydroxyprogesterone caproate, as well as other caproate progestogen esters such as gestonorone caproate. Hydroxyprogesterone caproate is a much more potent progestogen than 17α-hydroxyprogesterone, but does not have as high of affinity for the PR as progesterone. Hydroxyprogesterone caproate has about 26% and 30% of the affinity of progesterone for the human PR-A and PR-B, respectively. The medication was no more efficacious than progesterone in activating these receptors and eliciting associated gene expression in vitro.

Antigonadotropic effects

Due to activation of the PR, hydroxyprogesterone caproate has antigonadotropic effects, or produces suppression of the hypothalamic–pituitary–gonadal axis,[60] [61] and can significantly suppress gonadotropin secretion and gonadal sex hormone production at sufficiently high doses.[62] One study found that hydroxyprogesterone caproate by intramuscular injection at a dosage of 200 mg twice weekly for the first two weeks and then 200 mg once weekly for 12 weeks did not significantly influence urinary excretion of estrogens, luteinizing hormone, or follicle-stimulating hormone in men with benign prostatic hyperplasia.[63] In another study that used an unspecified dosage of intramuscular hydroxyprogesterone caproate, testosterone secretion was assessed in a single man and was found to decrease from 4.2 mg/day to 2.0 mg/day (or by approximately 52%) by 6 weeks of treatment, whereas secretion of luteinizing hormone remained unchanged in the man.[64] Yet another study found that 3,000 mg/week hydroxyprogesterone caproate by intramuscular injection suppressed testosterone levels from 640 ng/dL to 320–370 ng/dL (by 42–50%) in a single man with prostate cancer, which was similar to the testosterone suppression with cyproterone acetate or chlormadinone acetate.[65] Gestonorone caproate, a closely related progestin to hydroxyprogesterone caproate with about 5- to 10-fold greater potency in humans,[66] was found to suppress testosterone levels by 75% at a dosage of 400 mg/week in men with prostate cancer.[67] [68] For comparison, orchiectomy decreased testosterone levels by 91%. In general, progestins are able to maximally suppress testosterone levels by about 70 to 80%.[69] [70] [71] The antigonadotropic effects of hydroxyprogesterone caproate and hence its testosterone suppression are the basis of the use of hydroxyprogesterone caproate in the treatment of benign prostatic hyperplasia and prostate cancer in men. Suppression of luteinizing hormone levels by hydroxyprogesterone caproate has also been observed in women.[72] [73]

Glucocorticoid activity

Hydroxyprogesterone caproate is said not to have any glucocorticoid activity. In accordance, hydroxyprogesterone caproate has been found not to alter cortisol levels in humans even with very high doses by intramuscular injection. This is of relevance because medications with significant glucocorticoid activity suppress cortisol levels due to increased negative feedback on the hypothalamic–pituitary–adrenal axis.[74] [75] [76] Hydroxyprogesterone caproate has been studied in humans at doses as high as 5,000 mg per week by intramuscular injection, with safety and without glucocorticoid effects observed.[77] The medication does interact with the glucocorticoid receptor however; it has about 4% of the affinity of dexamethasone for the rabbit glucocorticoid receptor. But it acts as a partial agonist of the receptor and has no greater efficacy than progesterone in activating the receptor and eliciting associated gene expression in vitro.[78]

Other activities

As a pure progestogen, hydroxyprogesterone caproate has no androgenic, antiandrogenic, estrogenic, or glucocorticoid activity.[79] [80] The absence of androgenic and antiandrogenic activity with hydroxyprogesterone caproate is in contrast to most other 17α-hydroxyprogesterone-derivative progestins.[81] Due to its lack of androgenic properties, similarly to progesterone, hydroxyprogesterone caproate does not have any teratogenic effects on the fetus, making it safe for use during pregnancy. Although hydroxyprogesterone caproate has been described as a pure progestogen, there is evidence that it possesses some antimineralocorticoid activity, similarly to progesterone and 17α-hydroxyprogesterone.[82] [83] This includes clinically important diuretic effects and reversal of estrogen-induced fluid retention and edema. Unlike progesterone, hydroxyprogesterone caproate and its metabolites are not anticipated to interact with non-genomic receptors such as membrane progesterone receptors or the GABAA receptor. In accordance, hydroxyprogesterone caproate is not thought to possess the neurosteroid activities of progesterone or its associated sedative effects.

In relation to cytochrome P450 enzymes, hydroxyprogesterone caproate has no effect on CYP1A, CYP2D6, CYP2C9, or CYP3A4, but is a modest inducer of CYP2C19.

Differences from progesterone

There are pharmacodynamic differences between progesterone and hydroxyprogesterone caproate, which may have implications for obstetrical use.[84] [85] These include:

Differences in the metabolism of progesterone and hydroxyprogesterone caproate and differences in the formation and activities of metabolites may be responsible for or involved in these observed biological and pharmacological differences. Progesterone is metabolized by 5α- and 5β-reductases, 3α- and 3β-hydroxysteroid dehydrogenases, and 20α- and 20β-hydroxysteroid dehydrogenase in various tissues.[87] In target tissues, particularly the cervix and myometrium, these enzymes regulate local progesterone concentrations and can activate or inactivate progesterone signaling. In addition, these enzymes catalyze the formation of metabolites of progesterone such as 5β-dihydroprogesterone and allopregnanolone, which signal through their own non-genomic receptors such as membrane progesterone receptors and the GABAA receptor and have their own important effects in pregnancy.[88] [89] As examples, 5β-dihydroprogesterone has been found to play an important role in suppressing myometrial activity while allopregnanolone has potent sedative and anesthetic effects in the mother and especially the fetus and is involved in fetal nervous system development.[90] [91] In contrast to progesterone, hydroxyprogesterone caproate is not metabolized by traditional steroid-transforming enzymes and instead is metabolized exclusively via oxidation at the caproate side chain by cytochrome P450 enzymes. As such, it is not thought to have the same tissue-specific activation and inactivation patterns that progesterone does nor the same non-genomic actions that progesterone and its metabolites possess.

Further clinical research is anticipated to provide additional data to help clarify the issue of safety with hydroxyprogesterone caproate. In any case, it has been recommended by the American College of Obstetricians and Gynecologists that pregnant women treated with hydroxyprogesterone caproate receive counseling about its risks and benefits.

Pharmacokinetics

Pharmacokinetics of OHPCa in pregnant women
Parameter Singleton Twin
(ng/mL) 22.6 (15.8–27.4) 17.3 (12–27)
(ng/mL) 16.8 (12.8–22.7) 12.3 (8.4–18.7)
(ng/mL) 14.1 (10–18.1) 11.2 (4.8–16.3)
(ng/mL/day) 117.3 (89.9–159.1) 86.1 (59–131)
(days) 16.2 (10.6–21.0) 10 (6–16)
(days) 1.0 (1–3) 1.2 (1–2)
(×103) (L) 56 (25.2–69.6) 16.9 (9.1–24.5)
(×103) (L) 2.1 (1.5–2.7) 1.2 (0.9–1.7)
Footnotes: a = OHPC 250 mg once per week by intramuscular injection. Sources: [92] [93]

Absorption

In animals, the bioavailability of hydroxyprogesterone caproate with intramuscular injection is nearly 100%, but its oral bioavailability is very low at less than 3%.[94] In women, 70 mg/day oral hydroxyprogesterone caproate has similar endometrial potency as 70 mg/day oral OHPA and 2.5 mg/day oral medroxyprogesterone acetate, indicating that oral hydroxyprogesterone caproate and OHPA have almost 30-fold lower potency than medroxyprogesterone acetate via oral administration.[95] Studies on progestogenic endometrial changes with oral hydroxyprogesterone caproate in women are mixed however, with one finding weak effects with 100 mg/day whereas another found that doses of 250 to 1,000 mg produced no effects.[96] [97] As a result of its low oral potency, hydroxyprogesterone caproate has not been used by the oral route and has instead been administered by intramuscular injection. However, a novel oral formulation of hydroxyprogesterone caproate (developmental code name LPCN-1107) is under development and has been found to be effective, though it required administration twice a day in a clinical study.[98] [99] [100]

A depot effect occurs when hydroxyprogesterone caproate is injected intramuscularly or subcutaneously, such that the medication has a prolonged duration of action. Following a single intramuscular injection of 1,000 mg hydroxyprogesterone caproate in five women with endometrial cancer, peak levels of hydroxyprogesterone caproate were 27.8 ± 5.3 ng/mL and the time to peak concentrations was 4.6 ± 1.7 (3–7) days.[101] Following 13 weeks of continuous administration of 1,000 mg hydroxyprogesterone caproate per week, trough levels of hydroxyprogesterone caproate were 60.0 ± 14 ng/mL. The pharmacokinetic parameters of 250 mg hydroxyprogesterone caproate once per week by intramuscular injection have also been studied in pregnant women with singleton and multiple (twin and triplet) gestation. Steady state levels of the medication are achieved within 4 to 12 weeks of administration in pregnant women. The duration of clinical biological effect of hydroxyprogesterone caproate by intramuscular injection has also been studied in women.[102] A single intramuscular injection of 65 to 500 mg hydroxyprogesterone caproate in oil solution has been found to have a duration of action of 5 to 21 days in terms of effect in the uterus and on body temperature in women.

Hydroxyprogesterone caproate has been found to possess similar pharmacokinetics, including peak levels, time to peak levels, area-under-the-curve levels (i.e., total exposure), and elimination half-life, with administration via intramuscular injection or subcutaneous autoinjection.[103] However, there was a higher incidence of injection site pain with subcutaneous autoinjection than with intramuscular injection (37.3% vs. 8.2%).

Distribution

Hydroxyprogesterone caproate is extensively bound to plasma proteins, of which include albumin. Unlike progesterone and 17α-hydroxyprogesterone, hydroxyprogesterone caproate has very low affinity for corticosteroid-binding globulin (less than 0.01% of that of cortisol).[104] Progesterone and 17α-hydroxyprogesterone have low affinity for sex hormone-binding globulin, and for this reason, only a very small fraction of them (less than 0.5%) is bound to this protein in the circulation.[105]

Metabolism

Hydroxyprogesterone caproate appears to be metabolized primarily by the cytochrome P450 enzymes CYP3A4 and CYP3A5. It may also be metabolized by CYP3A7 in fetal liver and the placenta. Unlike progesterone, hydroxyprogesterone caproate is not metabolized by traditional steroid-transforming enzymes and does not form similar metabolites. The metabolism of hydroxyprogesterone caproate is by reduction, hydroxylation, and conjugation, including glucuronidation, sulfation, and acetylation. The caproate ester of hydroxyprogesterone caproate is not cleaved during metabolism, so 17α-hydroxyprogesterone is not formed from hydroxyprogesterone caproate.[106] As such, hydroxyprogesterone caproate is not a prodrug of 17α-hydroxyprogesterone, nor of progesterone.

Hydroxyprogesterone caproate has been found to have an elimination half-life of 7.8 days when given by intramuscular injection in an oil-based formulation to non-pregnant women. Its total duration is said to be 10 to 14 days, which is much longer than the duration of intramuscularly administered progesterone in an oil formulation (2 to 3 days). In pregnant women, the elimination half-life of hydroxyprogesterone caproate appears to be longer, about 16 or 17 days.[107] However, in women pregnant with twins rather than a singlet, the elimination half-life of hydroxyprogesterone caproate was found to be shorter than this, at 10 days. Hydroxyprogesterone caproate has been detected in pregnant women up to 44 days after the last dose.

Elimination

Hydroxyprogesterone caproate is eliminated 50% in feces and 30% in urine when given by intramuscular injection to pregnant women. Both the free steroid and conjugates are excreted by these routes, with the conjugates more prominent in feces.

Time–concentration curves

Chemistry

See also: List of progestogens, Progestogen ester and List of progestogen esters.

Hydroxyprogesterone caproate, also known as 17α-hydroxyprogesterone caproate or as 17α-hydroxypregn-4-ene-3,20-dione 17α-hexanoate, is a synthetic pregnane steroid and a derivative of progesterone.[108] [109] It is specifically a derivative of 17α-hydroxyprogesterone with a hexanoate (caproate) ester at the C17α position. Analogues of hydroxyprogesterone caproate include other 17α-hydroxyprogesterone derivatives such as algestone acetophenide (dihydroxyprogesterone acetophenide), chlormadinone acetate, cyproterone acetate, hydroxyprogesterone acetate, hydroxyprogesterone heptanoate, medroxyprogesterone acetate, and megestrol acetate, as well as the caproate esters chlormadinone caproate, gestonorone caproate (norhydroxyprogesterone caproate), medroxyprogesterone caproate, megestrol caproate, and methenmadinone caproate.

Synthesis

Chemical syntheses of hydroxyprogesterone caproate have been described.[110] [111] [112]

History

Along with hydroxyprogesterone acetate, hydroxyprogesterone caproate was developed by Karl Junkmann of Schering AG in 1953 and was first reported by him in the medical literature in 1954.[113] [114] [115] [116] [117] It was reportedly first marketed in Japan in 1954 or 1955,[118] and was subsequently introduced as Delalutin in the United States in 1956.[119] Due to its much longer duration than parenteral progesterone, hydroxyprogesterone caproate had largely replaced progesterone in clinical practice by 1975.[120] After decades of use, Squibb, the manufacturer, voluntarily withdrew the Delalutin product in the United States in 1999. Renewed interest in hydroxyprogesterone caproate in the United States was sparked with a large NIH-sponsored study in 2003 that found that hydroxyprogesterone caproate reduced the risk of premature birth in selected at-risk pregnant women. With follow-up data showing no evidence of harmful effects on the offspring, the FDA approved the medication Makena, sponsored by KV Pharmaceutical, as an orphan drug in February 2011 to reduce the risk of premature birth in women prior to 37 weeks gestation with a single fetus who had at least one previous premature birth.[121]

Under the FDA Accelerated Approval Programs, drugs that fill an unmet need for serious conditions can be approved based on a surrogate endpoint. The pharmaceutical company is required to conduct confirmatory studies to show the drug provides a clinical benefit.[122] The confirmatory trial, the PROLONG study, was completed in 2019 and showed no benefit in preventing preterm birth.[123] The FDA proposed withdrawal of approval for Makena in 2020. [124]

Society and culture

Names

Hydroxyprogesterone caproate is the generic name of OHPC and its,,, and, while hydroxyprogesterone hexanoate was its former .[125]

Hydroxyprogesterone caproate is often mislabeled as and confused with progesterone and 17α-hydroxyprogesterone.[126] It should also not be confused with hydroxyprogesterone acetate, hydroxyprogesterone heptanoate, or medroxyprogesterone acetate.

Hydroxyprogesterone caproate is marketed throughout the world under a variety of brand names including Proluton, Proluton Depot, and Makena, among many others. It was also formerly marketed under brand names including Delalutin, Prodrox, and Hylutin among others, but these formulations have been discontinued. It has been marketed under the brand names Gravibinon and Injectable No. 1 (or Chinese Injectable No. 1) in combination with estradiol valerate and under the brand name Primosiston in combination with estradiol benzoate.

Availability

See also: List of progestogens available in the United States.

Hydroxyprogesterone caproate is marketed in the United States and throughout Europe, Asia, and Central and South America.[127] It is not available in Canada, the United Kingdom, New Zealand, or South Africa, and only veterinary formulations are available in Australia. Hydroxyprogesterone caproate is also marketed in combination with estradiol valerate as a combined injectable contraceptive in a number of countries including in South America, Mexico, Japan, and China. It has been marketed as an injectable preparation in combination with estradiol benzoate in some countries as well.

Economics

With the designation of hydroxyprogesterone caproate as an orphan drug by the FDA and approval of Makena in 2011, the price of hydroxyprogesterone caproate in the United States was going to increase from to for a single dose, or from about to between and for a typical single month of treatment. This was about a 100-fold increase in cost, with "minimal added clinical benefit", and was a strongly criticized pricing strategy.[128] The FDA subsequently announced that compounding pharmacies could continue to sell hydroxyprogesterone caproate at their usual cost of approximately to per dose without fear of legal reprisals.[128] [129] KV Pharmaceutical also opted to reduced its price of Makena to per dose.[128] [130] Hydroxyprogesterone caproate continued to be available at low cost from compounding pharmacies until late 2016, after which time the FDA published new guidance documents prohibiting compounding pharmacies from selling products that are "essentially copies" of commercially available drug products.[131] [132]

Research

Cyclical therapy with 150 mg hydroxyprogesterone caproate by intramuscular injection was found to be effective in the treatment of 76 women with persistent, treatment-refractory acne in a preliminary study, with 84% responding to the therapy and experiencing a "good-to-excellent" improvement in symptoms.[133] [134]

Hydroxyprogesterone caproate was studied by Schering for use as a progestogen-only injectable contraceptive at a dose of 250 to 500 mg once a month by intramuscular injection but produced poor cycle control at these doses and was never marketed.[135] [136]

Hydroxyprogesterone caproate by itself has been found to have little or no effectiveness in the treatment of breast cancer in women.[137] [138] [139] Conversely, the combination of estradiol valerate and hydroxyprogesterone caproate has been found to be effective in the treatment of breast cancer in women.[140] [141] Initial research based on limited clinical data reported that the breast-cancer response rate with a combination of estradiol valerate and hydroxyprogesterone caproate seemed to be greater than with an estrogen alone (35% vs. 50%). However, subsequent research using the related but more potent progestin gestonorone caproate found that the combination of estradiol valerate and gestonorone caproate had effectiveness that was not significantly different from that of an estrogen alone in the treatment of breast cancer in women.[142]

Veterinary uses

The pharmacokinetics of hydroxyprogesterone caproate in various ungulates including cattle, buffalo, sheep, and goat have been studied.[143]

Further reading

Notes and References

  1. Onsrud M, Paus E, Haug E, Kjørstad K . Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function . Acta Obstetricia et Gynecologica Scandinavica . 64 . 6 . 519–23 . 1985 . 2932883 . 10.3109/00016348509156732 . 12007439 .
  2. News: Jewett C . 8 March 2023 . Preterm Birth Drug Withdrawn After 12 Years . The New York Times . 10 March 2023 . 10 March 2023 . https://web.archive.org/web/20230310001041/https://www.nytimes.com/2023/03/07/health/preterm-birth-drug-makena-fda.html . live .
  3. Web site: Dillinger K . 8 March 2023 . Maker of preterm birth drug Makena to withdraw it from market . 10 March 2023 . CNN . 10 March 2023 . https://web.archive.org/web/20230310093637/https://www.cnn.com/2023/03/08/health/makena-preterm-birth-withdrawn-covis/index.html . live .
  4. Covis Pharma Responds to Presiding Officer's Report Summarizing FDA Advisory Committee Hearing . Covis Pharma . GlobeNewswire . 7 March 2023 . 13 March 2023 . 13 March 2023 . https://web.archive.org/web/20230313233616/https://www.globenewswire.com/news-release/2023/03/07/2622609/0/en/Covis-Pharma-Responds-to-Presiding-Officer-s-Report-Summarizing-FDA-Advisory-Committee-Hearing.html . live .
  5. FDA Commissioner and Chief Scientist Announce Decision to Withdraw Approval of Makena . U.S. Food and Drug Administration . 6 April 2023 . 7 April 2023 . 6 April 2023 . https://web.archive.org/web/20230406150454/https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena . live .
  6. Web site: Hydroxyprogesterone caproate medicines to be suspended from the EU market . European Medicines Agency (EMA) . 17 May 2024 . 18 May 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. Deeks ED . 17 α-Hydroxyprogesterone caproate (Makena): in the prevention of preterm birth . Paediatric Drugs . 13 . 5 . 337–45 . October 2011 . 21888448 . 10.2165/11208140-000000000-00000 . 207297651 .
  8. Hines M, Lyseng-Williamson KA, Deeks ED . 17 α-hydroxyprogesterone caproate (Makena): a guide to its use in the prevention of preterm birth . Clinical Drug Investigation . 33 . 3 . 223–7 . March 2013 . 23413110 . 10.1007/s40261-013-0060-6 . 23221264 .
  9. Manuck TA . 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going? . Seminars in Perinatology . 41 . 8 . 461–467 . December 2017 . 28947068 . 10.1053/j.semperi.2017.08.004 . 36945947 . 2 November 2021 . 12 December 2020 . https://web.archive.org/web/20201212021914/https://cdr.lib.unc.edu/downloads/028712685 . live .
  10. Web site: Makena- hydroxyprogesterone caproate injection . DailyMed . 19 December 2022 . 13 March 2023 . 13 March 2023 . https://web.archive.org/web/20230313233619/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1998c1d-8337-4f00-8dcb-af3b54d39b77 . live .
  11. Newton JR, D'arcangues C, Hall PE . A review of "once-a-month" combined injectable contraceptives . Journal of Obstetrics and Gynaecology . 4 . Suppl 1 . S1-34 . 1994 . 12290848 . 10.3109/01443619409027641 .
  12. Book: Horsky J, Presl J. Ovarian Function and its Disorders: Diagnosis and Therapy. 6 December 2012. Springer Science & Business Media. 978-94-009-8195-9. 95–. 16 September 2018. 8 March 2023. https://web.archive.org/web/20230308182355/https://books.google.com/books?id=7IrpCAAAQBAJ&pg=PA95. live.
  13. Kim S. The Orphan Drug Act: How the FDA Unlawfully Usurped Market Exclusivity. Northwestern Journal of Technology and Intellectual Property. 11. [v&#93. Heinonline. 18 July 2016. 8 March 2023. https://web.archive.org/web/20230308182327/https://heinonline.org/HOL/LandingPage?handle=hein.journals%252Fnwteintp11&div=30&id=&page=. live.
  14. SMFM Clinical Guideline: Progesterone and preterm birth prevention: translating clinical trials data into clinical practice, AJOG May 2012
  15. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S . Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate . The New England Journal of Medicine . 348 . 24 . 2379–85 . June 2003 . 12802023 . 10.1056/NEJMoa035140 . free .
  16. Keirse MJ . Progesterone and preterm: seventy years of "déjà vu" or "still to be seen"? . Birth . 31 . 3 . 230–5 . September 2004 . 15330887 . 10.1111/j.0730-7659.2004.00315.x .
  17. Johnson JW, Austin KL, Jones GS, Davis GH, King TM . Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor . The New England Journal of Medicine . 293 . 14 . 675–80 . October 1975 . 1099445 . 10.1056/nejm197510022931401 .
  18. Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I, Lancet M . Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate . American Journal of Obstetrics and Gynecology . 151 . 5 . 574–7 . March 1985 . 3976757 . 10.1016/0002-9378(85)90141-3 .
  19. Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, Swain M, Bousleiman S, Johnson F, Dorman K, Milluzzi C, Tillinghast JA, Kerr M, Mallett G, Thom E, Pagliaro S, Anderson GD . Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo . Obstetrics and Gynecology . 110 . 4 . 865–72 . October 2007 . 17906021 . 10.1097/01.AOG.0000281348.51499.bc . 29485152 .
  20. Web site: Advisory Committees: CDER 2006 Meeting Documents . . 16 December 2019 . 8 May 2017 . https://web.archive.org/web/20170508161922/https://www.fda.gov/ohrms/dockets/ac/cder06.html#rhdac . live .
  21. Hendrickx AG, Korte R, Leuschner F, Neumann BW, Poggel A, Binkerd P, Prahalada S, Günzel P . Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate . Teratology . 35 . 1 . 129–36 . February 1987 . 3563931 . 10.1002/tera.1420350116 .
  22. Duke University Medical Center, New England Journal of Medicine, correspondence, vol 349.
  23. Hauth JC, Gilstrap LC, Brekken AL, Hauth JM . The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population . American Journal of Obstetrics and Gynecology . 146 . 2 . 187–90 . May 1983 . 6682631 . 10.1016/0002-9378(83)91051-7 .
  24. Norman JE, Marlow N, Messow CM, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J . Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial . en . Lancet . 387 . 10033 . 2106–2116 . May 2016 . 26921136 . 5406617 . 10.1016/S0140-6736(16)00350-0 .
  25. Web site: BMJ Blogs: The BMJ » Blog Archive » Richard Lehman's journal review—23 May 2016. blogs.bmj.com. 25 May 2016. 23 May 2016. 26 May 2016. https://web.archive.org/web/20160526090631/http://blogs.bmj.com/bmj/2016/05/23/richard-lehmans-journal-review-23-may-2016/. live.
  26. Dodd JM, Grivell RM, OBrien CM, Dowswell T, Deussen AR . Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy . The Cochrane Database of Systematic Reviews . 2019 . 11 . November 2019 . 31745984 . 6864412 . 10.1002/14651858.CD012024.pub3 .
  27. Reifenstein EC . Hydroxyprogesterone caproate therapy in advanced endometrial cancer . Cancer . 27 . 3 . 485–502 . March 1971 . 5549492 . 10.1002/1097-0142(197103)27:3<485::AID-CNCR2820270302>3.0.CO;2-1 . 37473914 . free .
  28. Book: Shoupe D, Mishell DR . Therapeutic Regimens . 335–351 . Mishell DR . Menopause: Physiology and Pharmacology . 1987 . Year Book Medical . 9780815159148 . 3 December 2019 . 8 March 2023 . https://web.archive.org/web/20230308182325/https://books.google.com/books?id=0q1sAAAAMAAJ . live .
  29. Agostini R, Casini ML, Costabile L, Paragona M, Marzano F, Unfer V . Efficacy and safety of 17alpha-hydroxyprogesterone caproate in hormone replacement therapy . Gynecological Endocrinology . 21 . 5 . 265–267 . November 2005 . 16373245 . 10.1080/09513590500368650 . 71508663 .
  30. Book: Benign Prostatic Hypertrophy. 6 December 2012. Springer Science & Business Media. 978-1-4612-5476-8. 266–. 3 October 2016. 11 January 2023. https://web.archive.org/web/20230111123403/https://books.google.com/books?id=Z5K-BwAAQBAJ&pg=PA266. live.
  31. Book: Ablin RJ, Mason MD . Metastasis of Prostate Cancer. 5 September 2007. Springer Science & Business Media. 978-1-4020-5847-9. 286–. 23 December 2018. 8 March 2023. https://web.archive.org/web/20230308182331/https://books.google.com/books?id=AAo2qVvcVJcC&pg=PA286. live.
  32. Book: Smith PH. Cancer of the Prostate and Kidney. 29 June 2013. Springer Science & Business Media. 978-1-4684-4349-3. 309, 339. 23 December 2018. 8 March 2023. https://web.archive.org/web/20230308182408/https://books.google.com/books?id=gtAFCAAAQBAJ&pg=PA309. live.
  33. Book: Hafez ES, Spring-Mills E. Prostatic Carcinoma: Biology and Diagnosis. 6 December 2012. Springer Science & Business Media. 978-94-009-8887-3. 128–. 23 December 2018. 8 March 2023. https://web.archive.org/web/20230308182339/https://books.google.com/books?id=XNt9BwAAQBAJ&pg=PT128. live.
  34. Book: Aronson JK . Meyler's Side Effects of Endocrine and Metabolic Drugs. 21 February 2009. Elsevier. 978-0-08-093292-7. 289–. 3 October 2016. 8 March 2023. https://web.archive.org/web/20230308182348/https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA289. live.
  35. Book: Israel GE, Tarver DE, Shaffer JD . Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts . 1 March 2001 . Temple University Press . 978-1-56639-852-7 . 58– . 3 October 2016 . 8 March 2023 . https://web.archive.org/web/20230308182350/https://books.google.com/books?id=IlPX6E5glDEC&pg=PA58 . live .
  36. Book: Ekins R, King D . The Transgender Phenomenon. 23 October 2006. SAGE Publications. 978-1-84787-726-0. 48–. 3 October 2016. 8 March 2023. https://web.archive.org/web/20230308182412/https://books.google.com/books?id=2TlvmbN9X7wC&pg=PA48. live.
  37. Book: Adler RK, Hirsch S, Mordaunt M . Voice and Communication Therapy for The Transgender/Transsexual Client: A Comprehensive Clinical Guide. 1 May 2012. Plural Publishing. 978-1-59756-631-5. 486–.
  38. Masumori N . Status of sex reassignment surgery for gender identity disorder in Japan . International Journal of Urology . 19 . 5 . 402–414 . May 2012 . 22372595 . 10.1111/j.1442-2042.2012.02975.x . 38888396 .
  39. Chekir C, Emi Y, Arai F, Kikuchi Y, Sasaki A, Matsuda M, Shimizu K, Tabuchi K, Kamada Y, Hiramatsu Y, Nakatsuka M . Altered arterial stiffness in male-to-female transsexuals undergoing hormonal treatment . The Journal of Obstetrics and Gynaecology Research . 38 . 6 . 932–940 . June 2012 . 22487218 . 10.1111/j.1447-0756.2011.01815.x . 18 August 2019 . live . 39877004 . https://web.archive.org/web/20230308182402/https://ousar.lib.okayama-u.ac.jp/en/48439 . 8 March 2023 .
  40. Book: Nema S, Ludwig JD . Pharmaceutical Dosage Forms - Parenteral Medications, Third Edition: Volume 1: Formulation and Packaging. 19 April 2016. CRC Press. 978-1-4200-8644-7. 161–. 15 September 2018. 8 March 2023. https://web.archive.org/web/20230308182421/https://books.google.com/books?id=Hkm3BgAAQBAJ&pg=PA161. live.
  41. Book: Muller NF, Dessing RP . European Drug Index: European Drug Registrations . Fourth . 19 June 1998 . CRC Press . 978-3-7692-2114-5 . 561– . 15 September 2018 . 8 March 2023 . https://web.archive.org/web/20230308182356/https://books.google.com/books?id=2HBPHmclMWIC&pg=PA561 . live .
  42. Garza-Flores J . Pharmacokinetics of once-a-month injectable contraceptives . Contraception . 49 . 4 . 347–59 . April 1994 . 8013219 . 10.1016/0010-7824(94)90032-9 .
  43. Sang GW . Pharmacodynamic effects of once-a-month combined injectable contraceptives . Contraception . 49 . 4 . 361–385 . April 1994 . 8013220 . 10.1016/0010-7824(94)90033-7 .
  44. Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S . Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control . World J Pharm Pharm Sci . 3 . 10 . 364–392 . 2014 . 2278-4357 . 15 September 2018 . https://web.archive.org/web/20170810000242/http://www.wjpps.com/download/article/1412071798.pdf . 10 August 2017 . dead .
  45. Book: Leidenberger FA . Klinische Endokrinologie für Frauenärzte. 17 April 2013. Springer-Verlag. 978-3-662-08110-5. 533–. 15 September 2018. 8 March 2023. https://web.archive.org/web/20230308182402/https://books.google.com/books?id=YTiuBgAAQBAJ&pg=PA533. live.
  46. Book: Kahr H . Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. 8 March 2013. Springer-Verlag. 978-3-7091-5694-0. 22–. 15 September 2018. 8 March 2023. https://web.archive.org/web/20230308182421/https://books.google.com/books?id=Hte1BgAAQBAJ&pg=PA22. live.
  47. Book: Kern W, Auterhoff H, Neuwald F, Schmid W. Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte und Medizinalbeamte. 9 March 2013. Springer-Verlag. 978-3-642-49759-9. 1163–. 15 September 2018. 8 March 2023. https://web.archive.org/web/20230308182347/https://books.google.com/books?id=C_SgBgAAQBAJ&pg=PA1163. live.
  48. Book: Ufer J . Die therapeutische Anwendung der Gestagene beim Menschen . Therapeutic Use of Progestogens in Humans . 1026–1124 . 10.1007/978-3-642-99941-3_7 . Die Gestagene . Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology . Progestogens . 1968 . Springer-Verlag . 978-3-642-99941-3 . Depotinjektionen [...] 2. Einmalige Injektion von 125mg oder 250mg 17α-Hydroxyprogesteroncapronat als Depotgestagen und 10 mg Oestradiolbenzoat in öliger Lösung (Primosiston) [47, 81, 110, 563, 523, 571, 718, 721, 732, 733, 864, 872, 933, 973, 400]. . 15 September 2018 . 8 March 2023 . https://web.archive.org/web/20230308182357/https://books.google.com/books?id=t8GpBgAAQBAJ&pg=PA1045 . live .
  49. Web site: EP Hormone - Drugs.com . 1 June 2019 . 7 April 2019 . https://web.archive.org/web/20190407210353/https://www.drugs.com/international/ep-hormone.html . dead .
  50. Noguchi M, Tajiri K, Taniya T, Kumaki T, Ashikari A, Miyazaki I . Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7) . Oncology . 47 . 1 . 19–24 . 1990 . 2137212 . 10.1159/000226779 . After the transplantation, each mouse received an intramuscular injection of 0.1 ml EP Hormone Depot consisting of 1 mg/ml 17-β-estradiol dipropionate and 50 mg/ml hydroxyprogesterone caproate every week..
  51. Tyler ET, Olson HJ . Fertility promoting and inhibiting effects of new steroid hormonal substances . J Am Med Assoc . 169 . 16 . 1843–54 . April 1959 . 13640942 . 10.1001/jama.1959.03000330015003 .
  52. Hall NR . What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone? . Obstetrics and Gynecology Clinics of North America . 38 . 2 . 235–46, ix–x . June 2011 . 21575799 . 10.1016/j.ogc.2011.02.014 .
  53. Book: Knörr K, Knörr-Gärtner H, Beller FK, Lauritzen C . Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion . 8 March 2013 . Springer-Verlag . 978-3-642-95583-9 . 583– . 29 March 2019 . 11 January 2023 . https://web.archive.org/web/20230111061914/https://books.google.com/books?id=tpmgBgAAQBAJ&pg=PA583 . live .
  54. Book: Knörr K, Beller FK, Lauritzen C . Lehrbuch der Gynäkologie . 17 April 2013 . Springer-Verlag . 978-3-662-00942-0 . 214, 255 . 15 September 2018 . 11 January 2023 . https://web.archive.org/web/20230111061914/https://books.google.com/books?id=ACybBwAAQBAJ&pg=PA214 . live .
  55. Lauritzen C . Clinical use of oestrogens and progestogens . Maturitas . 12 . 3 . 199–214 . September 1990 . 2215269 . 10.1016/0378-5122(90)90004-P .
  56. Toppozada MK . Existing once-a-month combined injectable contraceptives . Contraception . 49 . 4 . 293–301 . April 1994 . 8013216 . 10.1016/0010-7824(94)90029-9 .
  57. Siegel I . Conception control by long-acting progestogens: preliminary report . Obstetrics and Gynecology . 21 . 666–8 . June 1963 . 13992789 . 12 February 2020 . 12 February 2020 . https://web.archive.org/web/20200212204045/https://journals.lww.com/greenjournal/Citation/1963/06000/Conception_Control_by_Long_acting_Progestogens_.3.aspx . live .
  58. Kistner RW . The use of progestational agents in obstetrics and gynecology . Clinical Obstetrics and Gynecology . 3 . 4 . 1047–67 . December 1960 . 13756432 . 10.1097/00003081-196003040-00019 . 50 mg of [medroxyprogesterone acetate], intramuscularly, is equivalent to 250 mg [hydroxyprogesterone caproate] .
  59. Web site: Depo_Provera. FDA. 31 March 2018. 2016. 29 July 2020. https://web.archive.org/web/20200729234219/https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020246s058lbl.pdf. live.
  60. Yang D, Zhu RL . [Changes in reproductive hormones levels in the treatment of endometrial precancerous lesion with hydroxyprogesterone caproate] . zh . Zhonghua Fu Chan Ke Za Zhi . 29 . 4 . 205–6, 251 . April 1994 . 8082440 . In this paper, 14 cases of precancerous lesion of endometrium were treated with hydroxyprogesterone caproate and a series of hormone determination was analysed before and after treatment. Results showed that LH and LH/FSH were dramatically decreased. (LH P < 0.05, LH/FSH P < 0.01). .
  61. Book: Benign Prostatic Hypertrophy. 6 December 2012. Springer Science & Business Media. 978-1-4612-5476-8. 266–. Since the initial report by Geller and associates28 on the use of hydroxyprogesterone caproate in the treatment of BPH, a variety of progestins have been studied in the medical management of this disease: hydroxyprogesterone caproate, chlormadinone acetate,27 and medrogestone (6-methyl-6-dehydro-17-methylprogesterone).50 These drugs should have a beneficial effect in BPH as they inhibit testicular function by suppressing serum LH and have no intrinsic estrogenic or androgenic activity.. 3 October 2016. 11 January 2023. https://web.archive.org/web/20230111123403/https://books.google.com/books?id=Z5K-BwAAQBAJ&pg=PA266. live.
  62. Book: Castro JE . The Treatment of Prostatic Hypertrophy and Neoplasia. 9 March 2013. Springer Science & Business Media. 978-94-015-7190-6. 39,132. Geller has also demonstrated significant decreases in plasma or urine testosterone glucuronide levels following the administration of three other anti-androgens. These include Delalutin [hydroxyprogesterone caproate], chlormadinone acetate, and PH-218. It would appear that decreased androgen production is a property shared by all anti-androgens to date..
  63. Meiraz D, Margolin Y, Lev-Ran A, Lazebnik J . Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study . Urology . 9 . 2 . 144–8 . February 1977 . 65818 . 10.1016/0090-4295(77)90184-4 .
  64. Geller J, Bora R, Roberts T, Newman H, Lin A, Silva R . Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate: effect on clinical symptoms, morphology, and endocrine function . JAMA . 193 . 2 . 121–8 . July 1965 . 14304354 . 10.1001/jama.1965.03090020035009 .
  65. Geller J, Fruchtman B, Newman H, Roberts T, Silva R . Effect of progestational agents on carcinoma of the prostate . Cancer Chemother Rep . 51 . 1 . 41–6 . February 1967 . 6039663 .
  66. Karlstedt K . Progesterone treatment for local recurrence and metastases in carcinoma corporis uteri . Acta Radiologica . 10 . 2 . 187–92 . April 1971 . 5556820 . 10.3109/02841867109129755 . The preparations used were Proluton Depot (17a-hydroxy-progesterone caproate) and in 3 patients SH 5132 (17a-hydroxy-19-norprogesterone caproate); 100 mg of the latter corresponds to 1000 mg of Proluton Depot. . free .
  67. Sander S, Nissen-Meyer R, Aakvaag A . On gestagen treatment of advanced prostatic carcinoma . Scandinavian Journal of Urology and Nephrology . 12 . 2 . 119–21 . 1978 . 694436 . 10.3109/00365597809179977 .
  68. Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, Kahn F, Sood R, Joplin GF . Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men . Clinical Endocrinology . 11 . 5 . 497–504 . November 1979 . 519881 . 10.1111/j.1365-2265.1979.tb03102.x . 5836155 . Another synthetic gestogen, 17-hydroxy-19-norprogesterone caproate (Depostat-Schering), 400 mg by i.m. weekly injections suppressed T levels to 25% of pretreatment values (Sander er al., 1978). .
  69. Book: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA . Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set . 25 August 2011 . Elsevier Health Sciences . 978-1-4160-6911-9 . 2938– . 23 December 2018 . 11 January 2023 . https://web.archive.org/web/20230111061407/https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2938 . live .
  70. Knuth UA, Hano R, Nieschlag E . Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men . The Journal of Clinical Endocrinology and Metabolism . 59 . 5 . 963–9 . November 1984 . 6237116 . 10.1210/jcem-59-5-963 .
  71. Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R . Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial . British Journal of Urology . 52 . 3 . 208–15 . June 1980 . 7000222 . 10.1111/j.1464-410x.1980.tb02961.x .
  72. Sherman AI, Woolf RB . An endocrine basis for endometrial carcinoma . American Journal of Obstetrics and Gynecology . 77 . 2 . 233–42 . February 1959 . 13617315 . 10.1016/0002-9378(59)90223-6 .
  73. Moe N . Short-term progestogen treatment of endometrial carcinoma. Histological, histochemical and hormonal studies . Acta Obstetricia et Gynecologica Scandinavica . 51 . 1 . 55–62 . 1972 . 4261828 . 10.3109/00016347209154968 . 7181971 .
  74. Book: Becker KL . Principles and Practice of Endocrinology and Metabolism. 2001. Lippincott Williams & Wilkins. 978-0-7817-1750-2. 757–759, 2168. 2 February 2018. 8 March 2023. https://web.archive.org/web/20230308182345/https://books.google.com/books?id=FVfzRvaucq8C&pg=PA757. live.
  75. Book: Geer EB . The Hypothalamic-Pituitary-Adrenal Axis in Health and Disease: Cushing's Syndrome and Beyond. 1 December 2016. Springer. 978-3-319-45950-9. 28–. 2 February 2018. 8 March 2023. https://web.archive.org/web/20230308182358/https://books.google.com/books?id=Yw2kDQAAQBAJ&pg=PA28. live.
  76. Book: Aschenbrenner DS, Venable SJ . Drug Therapy in Nursing. 2009. Lippincott Williams & Wilkins. 978-0-7817-6587-9. 674–. 2 February 2018. 8 March 2023. https://web.archive.org/web/20230308182357/https://books.google.com/books?id=5zd_W_PUwvYC&pg=PA674. live.
  77. Varga A, Henriksen E. Clinical and Histopathologic Evaluation of the Effect of 17-alpha-Hydroxyprogesterone-17-n-caproate on Endometrial Carcinoma. Obstetrics & Gynecology. December 1961. Volume 18. Issue 6. pp. 658-672.
  78. Gerber AN, Masuno K, Diamond MI . Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening . Proceedings of the National Academy of Sciences of the United States of America . 106 . 12 . 4929–34 . March 2009 . 19255438 . 2660744 . 10.1073/pnas.0812308106 . 2009PNAS..106.4929G . free .
  79. Meis PJ . 17 hydroxyprogesterone for the prevention of preterm delivery . Obstetrics and Gynecology . 105 . 5 Pt 1 . 1128–35 . May 2005 . 15863556 . 10.1097/01.AOG.0000160432.95395.8f .
  80. Bardin CW, Brown T, Isomaa VV, Jänne OA . Progestins can mimic, inhibit and potentiate the actions of androgens . Pharmacology & Therapeutics . 23 . 3 . 443–59 . 1983 . 6371845 . 10.1016/0163-7258(83)90023-2 .
  81. Kuhl H . Pharmacology of estrogens and progestogens: influence of different routes of administration . Climacteric . 8 . Suppl 1 . 3–63 . August 2005 . 16112947 . 10.1080/13697130500148875 . 24616324 . 25 March 2018 . 22 August 2016 . https://web.archive.org/web/20160822055012/http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf . live .
  82. Book: Dorfman RI . Steroidal Activity in Experimental Animals and Man. 5 December 2016. Elsevier Science. 978-1-4832-7299-3. 398–. Intramuscular administration of 17α-hydroxyprogesterone caproate produced signs and symptoms of adrenal insufficiency in Addisonians maintained on cortisol and 9α-fluorocortisol (Melby, 1961) and thereby showed properties similar to progesterone and 17α-hydroxyprogesterone. However, further tests will be required to eludicate its pharmacodynamics properties. Contrastingly, there was no evidence for salt dissipation with the test of a smaller dose of the steroid to normal subjects (Landau et al., 1958).. 2 February 2018. 8 March 2023. https://web.archive.org/web/20230308182407/https://books.google.com/books?id=BbLfBAAAQBAJ&pg=PA398. live.
  83. Sammour MB, El-Kabarity H, Khalifa AS . Progesterone therapy in pre-eclamptic toxaemia . Acta Obstetricia et Gynecologica Scandinavica . 54 . 3 . 195–202 . 1975 . 1163210 . 10.3109/00016347509157760 . 38002155 . Melby (14) found that when progesterone was administered to patients suffering from the syndrome of idiopathic oedema, they experienced a diuresis, with a high excretion of sodium and water within 24 hours after a single injection of 500 mg of 17-α-hydroxyprogesterone caproate. .
  84. Romero R, Stanczyk FZ . Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice . American Journal of Obstetrics and Gynecology . 208 . 6 . 421–6 . June 2013 . 23643669 . 4120746 . 10.1016/j.ajog.2013.04.027 .
  85. Byrns MC . Regulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birth . The Journal of Steroid Biochemistry and Molecular Biology . 139 . 173–81 . January 2014 . 23410596 . 10.1016/j.jsbmb.2013.01.015 . 23414730 .
  86. Anderson L, Martin W, Higgins C, Nelson SM, Norman JE . The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy . Reproductive Sciences . 16 . 11 . 1052–61 . November 2009 . 19602723 . 10.1177/1933719109340926 . 6856556 .
  87. Book: Cupps PT . Reproduction in Domestic Animals. 20 February 1991. Elsevier. 978-0-08-057109-6. 101–.
  88. Gellersen B, Fernandes MS, Brosens JJ . Non-genomic progesterone actions in female reproduction . Human Reproduction Update . 15 . 1 . 119–38 . 2009 . 18936037 . 10.1093/humupd/dmn044 . free .
  89. Schumacher M, Mattern C, Ghoumari A, Oudinet JP, Liere P, Labombarda F, Sitruk-Ware R, De Nicola AF, Guennoun R . Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors . Progress in Neurobiology . 113 . 6–39 . February 2014 . 24172649 . 10.1016/j.pneurobio.2013.09.004 . 11336/6678 . 207407117 . free .
  90. Mellor DJ, Diesch TJ, Gunn AJ, Bennet L . The importance of 'awareness' for understanding fetal pain . Brain Research. Brain Research Reviews . 49 . 3 . 455–71 . November 2005 . 16269314 . 10.1016/j.brainresrev.2005.01.006 . 9833426 .
  91. Lagercrantz H, Changeux JP . The emergence of human consciousness: from fetal to neonatal life . Pediatric Research . 65 . 3 . 255–60 . March 2009 . 19092726 . 10.1203/PDR.0b013e3181973b0d . 39391626 . [...] the fetus is sedated by the low oxygen tension of the fetal blood and the neurosteroid anesthetics pregnanolone and the sleep-inducing prostaglandin D2 provided by the placenta (36). . free . 18 August 2019 . 15 October 2021 . https://web.archive.org/web/20211015090548/https://philpapers.org/rec/LAGTEO-5 . live .
  92. Caritis SN, Sharma S, Venkataramanan R, Hankins GD, Miodovnik M, Hebert MF, Umans JG, Benedetti T, Mattison D, Zajicek A, Fischer D, Jackson A . Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation . American Journal of Obstetrics and Gynecology . 207 . 5 . 398.e1–8 . November 2012 . 22967833 . 3586341 . 10.1016/j.ajog.2012.08.015 .
  93. Caritis SN, Sharma S, Venkataramanan R, Rouse DJ, Peaceman AM, Sciscione A, Spong CY, Varner MW, Malone FD, Iams JD, Mercer BM, Thorp JM, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M . Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation . American Journal of Obstetrics and Gynecology . 205 . 1 . 40.e1–8 . July 2011 . 21620357 . 3165062 . 10.1016/j.ajog.2011.03.028 .
  94. Shaik IH, Bastian JR, Zhao Y, Caritis SN, Venkataramanan R . Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats . Xenobiotica; the Fate of Foreign Compounds in Biological Systems . 46 . 2 . 169–74 . 2015 . 26153441 . 4809632 . 10.3109/00498254.2015.1057547 .
  95. Book: Ferin J . Orally Active Progestational Compounds. Human Studies: Effects on the Utero-Vaginal Tract . 245–273 . Tausk M . Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents . II . https://books.google.com/books?id=Nv5sAAAAMAAJ . September 1972 . Pergamon Press . 978-0080168128 . 278011135.
  96. Boschann HW . Observations of the role of progestational agents in human gynecologic disorders and pregnancy complications . Ann. N. Y. Acad. Sci. . 71 . 5 . 727–52 . July 1958 . 13583829 . 10.1111/j.1749-6632.1958.tb46803.x . 1 July 2024 . 1958NYASA..71..727B .
  97. Pots P . Die perorale wirksamkeit synthetischer gestagene . The effectiveness of peroral synthetic gestagens . de . Zentralbl Gynakol . 79 . 14 . 529–39 . April 1957 . 13443471 .
  98. Web site: Hydroxyprogesterone caproate oral - Lipocine - AdisInsight . 24 February 2019 . 1 November 2017 . https://web.archive.org/web/20171101140919/http://adisinsight.springer.com/drugs/800038483 . live .
  99. DelConte A, Chidambaram N, Nachaegari S, Patel M, Venkateshwaran S . 770: Pharmacokinetics and tolerability of oral 17-hydroxyprogesterone caproate (HPC) relative to intramuscular (IM) HPC. . American Journal of Obstetrics & Gynecology . January 2015 . 212 . 1 . S374 . 10.1016/j.ajog.2014.10.976 .
  100. Boggess KA, Baker JB, Murtha AP, Peaceman AM, Shah DM, Siegfried SL, Birch R . Pharmacokinetics of Hydroxyprogesterone Caproate and its Primary Metabolites during Pregnancy . AJP Reports . 8 . 2 . e106–e112 . April 2018 . 29765789 . 5951785 . 10.1055/s-0038-1639331 .
  101. Web site: Highlight of Prescribing Information: MAKENATM (hydroxyprogesterone caproate injection) for intramuscular use. . February 2011 . U.S. Food and Drug Administration . https://web.archive.org/web/20170227232340/http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021945s000lbl.pdf . 27 February 2017 .
  102. Book: Ferin J . Effects, Duration of Action and Metabolism in Man . 13–24 . Tausk M . Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents . II . https://books.google.com/books?id=Nv5sAAAAMAAJ . September 1972 . Pergamon Press . 978-0080168128 . 278011135.
  103. Krop J, Kramer WG . Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study . Clinical Therapeutics . 39 . 12 . 2345–2354 . December 2017 . 29191450 . 10.1016/j.clinthera.2017.10.020 . free .
  104. Mickelson KE, Forsthoefel J, Westphal U . Steroid-protein interactions. Human corticosteroid binding globulin: some physicochemical properties and binding specificity . Biochemistry . 20 . 21 . 6211–8 . October 1981 . 7306509 . 10.1021/bi00524a047 .
  105. Dunn JF, Nisula BC, Rodbard D . Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma . The Journal of Clinical Endocrinology and Metabolism . 53 . 1 . 58–68 . July 1981 . 7195404 . 10.1210/jcem-53-1-58 .
  106. Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN . Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins . American Journal of Obstetrics and Gynecology . 197 . 6 . 599.e1–7 . December 2007 . 18060946 . 2278032 . 10.1016/j.ajog.2007.05.024 .
  107. Feghali M, Venkataramanan R, Caritis S . Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations . Seminars in Perinatology . 38 . 8 . 516–22 . December 2014 . 25256193 . 4253874 . 10.1053/j.semperi.2014.08.013 .
  108. Book: Index Nominum 2000: International Drug Directory. January 2000. Taylor & Francis. 978-3-88763-075-1. 532–.
  109. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 664–.
  110. Book: Engel J, Kleemann A, Kutscher B, Reichert D . Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs . 14 May 2014 . Thieme . 978-3-13-179275-4 . 677–679 . 6 September 2018 . 8 March 2023 . https://web.archive.org/web/20230308182347/https://books.google.com/books?id=4lCGAwAAQBAJ&pg=PA677 . live .
  111. Book: William Andrew Publishing . Pharmaceutical Manufacturing Encyclopedia . 22 October 2013 . Elsevier . 978-0-8155-1856-3 . 1865–1866 . 6 September 2018 . 8 March 2023 . https://web.archive.org/web/20230308182939/https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1865 . live .
  112. Book: Junkmann K, Langecker H, Damrosch L . Chemie der Gestagene . Chemistry of Progestogens . 1–44 . 10.1007/978-3-642-99941-3_1 . Die Gestagene . Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology . Progestogens . 1968 . Springer-Verlag . 978-3-642-99941-3 . 3. Hydroxyprogesteron-caproat. C27H4004, Mol.-Gew.: 428,62; chemische Bezeichnung Δ4-Pregnen-17α-ol-3,20-dion-17α-capronat, Trivialnamen: Hydroxyprogesteroncapronat, 17α-Hydroxyprogesteron-17α-capronat. Synthese: [88]. Darstellung: [88]. Eigenschaften: weißes kristallines Pulver (aus Isopropyläther) oder Methanol, F.: 119-122⁰, [α]D: +60⁰ (Chlf.) UV-Absorption: λmax.: 240 mμ, ε = 17000. Dipolmoment: [μ = 2,21 (Benzol). Leicht löslich in Äthanol, Äther, Essigester, Benzol, Chloroform, löslich in: Petroläther, unlöslich in Wasser. Bei 20⁰ lösen 100 ml Sesamöl ca. 4,0 g, Ricinusöl ca. 2,5 g, Ricinusöl: Benzylbenzoat (4: 6) ca. 26,5 g, Benzylbenzoat ca. 36,0 g. [...] Abb. 3. IR-Spektrum [126] und Formel des Hydroxyprogesteron-caproat. | access-date = 15 September 2018 | archive-date = 8 March 2023 | archive-url = https://web.archive.org/web/20230308182357/https://books.google.com/books?id=t8GpBgAAQBAJ&pg=PA1045 | url-status = live .
  113. Junkmann K . Über protrahiert wirksame Gestagene. Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie. 223. 3. 1954 . 10.1007/BF00246995. 33591186 .
  114. Wied GL, Davis ME . Comparative activity of progestational agents on the human endometrium and vaginal epithelium of surgical castrates . Annals of the New York Academy of Sciences . 71 . 5 . 599–616 . July 1958 . 13583817 . 10.1111/j.1749-6632.1958.tb46791.x . 1 July 2024 . In the group of new parenteral progestational agents, three substances developed by Karl Junkmann1,2 are the most outstanding and interesting: 17a-hydroxyprogesterone caproate and 17a-hydroxyprogesterone acetate, introduced in 1953, and the most potent of all new parenteral progestational agents, 17-ethynyl-19-nortestosterone enanthate, introduced in 1956. . 1958NYASA..71..599W .
  115. Book: ACRH. 1960. U.S. Dept. of Energy. 71. [The] minimal activity [of 17(a)-hydroxyprogesterone] is magnified to an unexpected degree by the esterification of this steroid with caproic acid to produce 17(a)-hydroxyprogesterone-17-n-caproate, first reported by Karl Junkmann in 1954.6,7.
  116. Book: Dorfman RI . Methods in Hormone Research. 1966. Academic Press. 86. Junkmann (1954) reported that the acetate, butyrate, and caproate forms had both increased and prolonged activity, [...].
  117. Book: Applezweig N . Steroid Drugs. 1962. Blakiston Division, McGraw-Hill. 101–102. Junkmann of Schering, AG., however, was able to show that long chain esters of 17a-hydroxyprogesterones such as the 17a-caproate produced powerful long-acting progestational effect. This compound is marketed in the United States as Delalutin by Squibb, and has been heavily used for the treatment of habitual abortion..
  118. Book: International Agency for Research on Cancer. Sex Hormones (II).. 1979. International Agency for Research on Cancer. 978-92-832-1221-8. 401. 17α-Hydroxyprogesterone caproate was first marketed commercially in Japan in 1954-1955..
  119. Book: New and Nonofficial Drugs. 1958. Lippincott. 662. Supplied by.—E. R. Squibb & Sons (Delalutin). Year of introduction: 1956..
  120. Book: Tausk M . Pharmacology of hormones. 1975. Thieme. 978-3-13-518901-7. 105. Progesterone itself is now almost never used for the management of any imminent threat to pregnancy. For oral therapy, it is in any event unsuitable and for injections, it has now been replaced by the long-acting esters of 17α-hydroxyprogesterone. The caproate (Proluton, Delalutin), a long-acting ester, is available in [...] Progesterone is rarely used therapeutically. It has largely been superseded by a long-acting ester of 17α-hydroxyprogesterone, for parenteral therapy..
  121. Web site: FDA press release regarding Makena approval . . 16 December 2019 . 18 January 2017 . https://web.archive.org/web/20170118093045/http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm242234.htm . live .
  122. Web site: Accelerated Approval Program . . 30 January 2023 . 14 March 2023 . live . 13 March 2023 . https://web.archive.org/web/20230313171707/https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program .
  123. Blackwell, SC, et al . 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial . American Journal of Perinatology . 37 . 2 . 127–136 . January 2020. 31652479 . 10.1055/s-0039-3400227 . 204908640 . free .
  124. Web site: CDER proposes withdrawal of approval for Makena . . 5 October 2020 . 14 March 2023 . live . 7 April 2023 . https://web.archive.org/web/20230407220250/https://www.fda.gov/drugs/drug-safety-and-availability/cder-proposes-withdrawal-approval-makena .
  125. Web site: Hydroxyprogesterone . 29 July 2017 . 29 July 2017 . https://web.archive.org/web/20170729131704/https://www.drugs.com/international/hydroxyprogesterone.html . live .
  126. O'Brien JM . Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens . Ultrasound in Obstetrics & Gynecology . 42 . 3 . 247–53 . September 2013 . 23495199 . 10.1002/uog.12456 . 45600479 . free .
  127. Book: Sweetman SC . Sex hormones and their modulators . Martindale: The Complete Drug Reference . 36th . 2009 . 2110–2111 . Pharmaceutical Press . London. 978-0-85369-840-1.
  128. Armstrong J . Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP . The New England Journal of Medicine . 364 . 18 . 1689–91 . May 2011 . 21410391 . 10.1056/NEJMp1102796 . free .
  129. Web site: Macleans.ca - Canada's national current affairs and news magazine since 1905 . 30 March 2011 . dead . https://web.archive.org/web/20111214041544/http://www.macleans.ca/article.jsp?content=w6411446 . 14 December 2011 .
  130. News: Price of preterm birth medicine cut. Boston.com. Associated Press. 2 April 2011. 2 April 2011. 3 November 2012. https://web.archive.org/web/20121103054918/http://www.boston.com/news/nation/washington/articles/2011/04/02/price_of_preterm_birth_medicine_cut/. live.
  131. Web site: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry. 1 April 2019. U.S. Food and Drug Administration. 14 June 2019. 19 June 2019. https://web.archive.org/web/20190619220220/https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounded-drug-products-are-essentially-copies-commercially-available-drug-product-under-section. live.
  132. Web site: FDA to Restrict Compounders from Making Copies of Commercially Available Drugs. 7 July 2016. RAPS.com. 14 June 2019. 6 October 2019. https://web.archive.org/web/20191006145556/https://www.raps.org/regulatory-focus%E2%84%A2/news-articles/2016/7/fda-to-restrict-compounders-from-making-copies-of-commercially-available-drugs. live.
  133. Baker KC . Treatment of persistent acne in women with 17 alpha hydroxyprogesterone caproate (delalutin); a preliminary report . The Journal of Investigative Dermatology . 31 . 5 . 247–50 . November 1958 . 13598928 . 10.1038/jid.1958.114 . free .
  134. Book: Antibiotic Medicine and Clinical Therapy . 1959 . 249.
  135. Book: Toppozada MK . Monthly Injectable Contraceptives . 93–103 . Goldsmith A, Toppozada M . Long-Acting Contraception . 1983 . 35018604 . 27 December 2019 . 10 June 2022 . https://web.archive.org/web/20220610034743/https://scholar.google.com/scholar?cluster=14664537528797672080 . live .
  136. Toppozada M . The clinical use of monthly injectable contraceptive preparations . Obstetrical & Gynecological Survey . 32 . 6 . 335–47 . June 1977 . 865726 . 10.1097/00006254-197706000-00001 .
  137. Book: Dao TL . Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms . 1975 . 170–192 . 10.1007/978-3-642-65806-8_11 . Sartorelli AC, Johns DG . Antineoplastic and Immunosuppressive Agents . Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology . Springer . https://books.google.com/books?id=aU_oCAAAQBAJ&pg=PA170 . 978-3-642-65806-8 . 31 May 2019 . 10 January 2023 . https://web.archive.org/web/20230110033051/https://books.google.com/books?id=aU_oCAAAQBAJ&pg=PA170 . live .
  138. Crowley LG, Macdonald I . Clinical trial of delautin in the treatment of advanced mammary carcinoma in postmenopausal women . Cancer . 15 . 6 . 1218–1220 . 1962 . 14024037 . 10.1002/1097-0142(196211/12)15:6<1218::AID-CNCR2820150619>3.0.CO;2-Y . 8005246 .
  139. Geller J, Volk H, Lewin M . Objective remission of metastatic breast carcinoma in a male who received 17-alpha hydroxy progesterone caproate (delalutin) . Cancer Chemotherapy Reports . 14 . 77–81 . October 1961 . 13897631 .
  140. Crowley LG, Macdonald I . Delalutin and estrogens for the treatment of advanced mammary carcinoma in the postmenopausal woman . Cancer . 18 . 4 . 436–446 . April 1965 . 14278040 . 10.1002/1097-0142(196504)18:4<436::AID-CNCR2820180407>3.0.CO;2-D . 31370289 .
  141. Crowley LG, MacDonald J . Delalutin und Östrogene als Behandlung des vorgeschrittenen Mammakarzinoms bei Frauen nach der Menopause. Delalutin and estrogens as a treatment for advanced breast cancer in postmenopausal women. Gynäkologisch-geburtshilfliche Rundschau. 3. 4. 1966. 271–272. 1018-8843. 10.1159/000266855. free.
  142. Firusian N, Schietzel M . [Additive treatment of metastasizing breast cancer with special reference to postmenopausal age (results of a randomized study)] . de . Strahlentherapie . 152 . 3 . 235–247 . September 1976 . 968923 . Additive treatment of metastasizing breast cancer with special reference to postmenopausal age (results of a randomized study) .
  143. Santhosh CR . 2006 . Pharmacokinetics of 17α-Hydroxy Progesterone Caproate in Cattle, Buffalo, Sheep and Goat . Ph.D. . Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar . https://web.archive.org/web/20181215224604/http://krishikosh.egranth.ac.in/handle/1/68575 . 15 December 2018 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Hydroxyprogesterone caproate".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.